ART104

ART104 is an antibody against a novel cancer target.

Currently in the advanced discovery stage of development and the late stages of ‘humanisation’, ART104 has been shown to improve the effects of standard chemotherapy in a mouse model of colorectal cancer.

Although ART104 is under development for colorectal cancer, Arana anticipates that it may also be effective for the treatment of other solid tumours.

The market for all anti-cancer drugs is more than US$20 billion annually. The market for a drug against any one solid tumour is estimated to be about US$500 million.

Arana is likely to take a decision on the form of ART104 it will develop clinically within 18 months, following the completion of preclinical studies.